CAMBRIDGE, UK, April 8, 2026
Immutrin Ltd has successfully raised £65 million ($87 million) in an oversubscribed Series A financing round to advance its next-generation antibody therapy targeting ATTR amyloidosis, a serious and progressive disease with high unmet medical need. The funding will support the company’s lead asset through clinical proof of concept, positioning it as a potential best-in-class biologic therapy designed to remove existing amyloid deposits and reverse disease progression.
Next-Generation Antibody Targets Root Cause of Amyloidosis
Immutrin’s innovative therapeutic approach focuses on directly removing pre-existing amyloid fibrils from tissues, addressing a critical gap in current treatment strategies. Existing therapies primarily aim to slow or suppress amyloid production, but they do not effectively eliminate already accumulated deposits, which continue to cause organ damage.
The company’s lead antibody is engineered to selectively bind to amyloid fibrils and activate a targeted immune response, enabling efficient clearance of these deposits from affected tissues. This mechanism has the potential to restore organ function and improve long-term clinical outcomes, particularly in patients with ATTR cardiomyopathy, a life-threatening condition associated with progressive heart failure.
Importantly, the therapy is based on decades of scientific research in amyloidosis and antibody engineering, combining insights into immune-mediated amyloid clearance with advanced biologic design. This positions Immutrin’s candidate as a highly differentiated therapy with potential applications beyond ATTR, including other forms of amyloidosis.
Advertisement
Strong Investor Support Accelerates Clinical Development
The Series A financing was led by Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One, and Cambridge Innovation Capital, reflecting strong investor confidence in the company’s scientific approach and therapeutic potential.
The capital raised will enable Immutrin to advance its lead asset into clinical studies, focusing on achieving proof of concept in ATTR cardiomyopathy. This milestone is critical for demonstrating the therapy’s safety, efficacy, and clinical benefit, paving the way for further development and regulatory engagement.
In addition to funding, the financing round strengthens the company’s leadership, with key investors joining the board of directors. This provides Immutrin with strategic guidance, industry expertise, and global development capabilities, essential for navigating the complex drug development and regulatory landscape.
Transforming Treatment Landscape for Rare Diseases
Amyloidosis represents a group of rare but devastating diseases caused by misfolded proteins that accumulate in tissues, leading to progressive organ dysfunction and high mortality. Despite recent advances, effective removal of amyloid deposits remains a major unmet need, limiting the impact of current therapies.
Immutrin’s approach aims to transform the treatment paradigm by targeting the underlying pathology of the disease, rather than merely slowing its progression. By enabling active clearance of amyloid deposits, the therapy has the potential to deliver disease-modifying benefits, improving both survival and quality of life for patients.
The company’s focus on precision biologics and immune-mediated mechanisms reflects broader trends in biopharmaceutical innovation, where targeted therapies are increasingly being developed to address complex diseases at their source. If successful, Immutrin’s antibody could represent a breakthrough in the treatment of amyloidosis and related conditions, offering new hope for patients with limited therapeutic options.
Immutrin’s successful Series A financing marks a significant milestone in the development of next-generation antibody therapies for amyloidosis, enabling the company to advance its lead candidate toward clinical validation. With its innovative mechanism of action, strong investor backing, and focus on addressing unmet medical needs, Immutrin is well-positioned to play a transformative role in the future of biopharmaceutical innovation and rare disease treatment.
Source: Immutrin press release
